Literature DB >> 16407848

CXCR4 expression mediates glioma cell invasiveness.

M Ehtesham1, J A Winston, P Kabos, R C Thompson.   

Abstract

Glioblastoma multiforme is a highly invasive tumor bearing a dismal prognosis. Experimental strategies that focus on the specific biological cues governing the invasive capacity of these tumors may hold significant therapeutic promise. In this context, we describe the in vitro and in vivo association of the cell surface chemokine receptor, CXCR4, with the development of an invasive phenotype in malignant glioblastoma. We demonstrate that invasive populations of glioma cells overexpress CXCR4 at the message and protein levels, and that this expression ranges from 25- to 89-fold higher than that found in noninvasive tumor cells. Furthermore, neutralization of CXCR4 significantly impairs the in vitro invasive capacity of malignant glial cells. In addition, glioma cells secrete CXCL12 and demonstrate robust invasive capacity toward a CXCL12 gradient in vitro. These findings underscore the importance of CXCR4 as a potential therapeutic target for the treatment of invasive glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16407848     DOI: 10.1038/sj.onc.1209302

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  68 in total

Review 1.  Migration and fate of therapeutic stem cells in different brain disease models.

Authors:  B J Carney; K Shah
Journal:  Neuroscience       Date:  2011-09-14       Impact factor: 3.590

2.  CXCL12-CXCR4/CXCR7 axis contributes to cell motilities of oral squamous cell carcinoma.

Authors:  Na Chen; Xiao Jiang; Juan Wang; Tong Wu; Bin Cheng; Juan Xia
Journal:  Tumour Biol       Date:  2015-08-02

Review 3.  G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues.

Authors:  A E Cherry; N Stella
Journal:  Neuroscience       Date:  2014-08-24       Impact factor: 3.590

Review 4.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

5.  Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures.

Authors:  David Zagzag; Mine Esencay; Olga Mendez; Herman Yee; Iva Smirnova; Yuanyuan Huang; Luis Chiriboga; Eugene Lukyanov; Mengling Liu; Elizabeth W Newcomb
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

Review 6.  Testicular germ cell tumours: predisposition genes and the male germ cell niche.

Authors:  Duncan Gilbert; Elizabeth Rapley; Janet Shipley
Journal:  Nat Rev Cancer       Date:  2011-03-17       Impact factor: 60.716

Review 7.  The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences.

Authors:  Estelle Willems; Arnaud Lombard; Matthias Dedobbeleer; Nicolas Goffart; Bernard Rogister
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

8.  CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities.

Authors:  Charles B Stevenson; Moneeb Ehtesham; Kathryn M McMillan; J Gerardo Valadez; Michael L Edgeworth; Ronald R Price; Ty W Abel; Khubaib Y Mapara; Reid C Thompson
Journal:  Neurosurgery       Date:  2008-09       Impact factor: 4.654

Review 9.  The role of the CXCR4 cell surface chemokine receptor in glioma biology.

Authors:  Moneeb Ehtesham; Elliot Min; Neil M Issar; Rebecca A Kasl; Imad S Khan; Reid C Thompson
Journal:  J Neurooncol       Date:  2013-03-14       Impact factor: 4.130

10.  Effects of tyrosine kinase inhibitors and CXCR4 antagonist on tumor growth and angiogenesis in rat glioma model: MRI and protein analysis study.

Authors:  Meser M Ali; Sanath Kumar; Adarsh Shankar; Nadimpalli R S Varma; A S M Iskander; Branislava Janic; Wilson B Chwang; Rajan Jain; Abbas Babajeni-Feremi; Thaiz F Borin; Hassan Bagher-Ebadian; Stephen L Brown; James R Ewing; Ali S Arbab
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.